Company profile: Arresto Biosciences
1.1 - Company Overview
Company description
- Provider of medicine development targeting extracellular matrix molecules to treat cancer and fibrotic diseases.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Arresto Biosciences
Sellas Life Sciences
HQ: Bermuda
Website
- Description: Provider of late-stage cancer immunotherapies, developing Galinpepimut-S (GPS), a WT1-targeting synthetic heteroclitic epitope immunotherapeutic for various cancers to prevent relapses and potentially improve survival, and SLS009, a highly selective small molecule CDK9 inhibitor for development and commercialization worldwide outside the Greater China Region.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sellas Life Sciences company profile →
Bavarian Nordic
HQ: Denmark
Website
- Description: Provider of novel vaccines for the treatment and prevention of life-threatening diseases with large unmet medical need, focused on biodefence, cancer and infectious diseases. Product portfolio includes MVA-BN, a non-replicating vaccine for immunization against smallpox and mpox, approved in various countries and supplied to national stockpiles.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bavarian Nordic company profile →
NexImmune
HQ: United States
Website
- Description: Provider of immuno-therapeutics using proprietary AIM artificial immune technology, including AIM ACT, a cellular therapy using AIM nanoparticles to orchestrate specific T cell functions for cancer treatment; AIM INJ, an injectable AIM nanoparticle product targeting disease-specific T cells; and Phase 1/2 candidates NEXI-001 (AML) and NEXI-002 (multiple myeloma).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NexImmune company profile →
Stallergenes Greer
HQ: United Kingdom
Website
- Description: Provider of allergy immunotherapy products and services and molecular diagnostics for respiratory allergies, spanning sublingual and oral treatments for allergic rhinitis, asthma, grass pollen, house dust mite, and peanut allergies. Products include Staloral, Oralair, Actair, Palforzia, SLIT-liquid, and tools to identify specific allergens to guide prescription and composition of immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stallergenes Greer company profile →
Maverick Therapeutics
HQ: United States
Website
- Description: Provider of T cell immunotherapies for solid tumor cancers, developing breakthrough treatments with improved safety and efficacy via COBRA, the most advanced bispecific T cell engaging platform in its class designed to safely target solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Maverick Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Arresto Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Arresto Biosciences
2.2 - Growth funds investing in similar companies to Arresto Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Arresto Biosciences
4.2 - Public trading comparable groups for Arresto Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →